UNSPSC 51283952: Sulfarsphenamine

This classification denotes a topical anti-infective agent with the molecular formula C14H14As2N2O8S2.2Na, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier B1GGH4ZUZL, chemically known as 3,3-diamino-4,4-dihydroxyarsenobenzol-n,n-methanesulfonsaeure dinatrium salz but more generally known as sulfarsphenamine, which bears U.S. National Institutes of Health Compound Identifier 71510. The European Medicines Agency schedules Sulfarsphenamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10726MIG.

The term SULFARSPHENAMINE is an International Non-Proprietary Name. SULFARSPHENAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: [ASH](=[ASH]\C1CC(NCS(=O)(=O)O)C(O)CC1)/C1CC(NCS(=O)(=O)O)C(O)CC1.[NA].[NA].

UNSPSC 51283952 Sulfarsphenamine is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, but the recent opportunities record shows minimal activity specifically tied to this code. The four most recent state and local solicitations tagged under this code—ranging from a Seminole County naloxone and drug deactivation systems IFB to a Minnesota cooperative purchasing RFP for generic pharmaceuticals and OTC products—do not reflect procurement of sulfarsphenamine itself. Instead, they reflect broader public health supply acquisition: emergency response medications (naloxone), pharmacy benefit program innovation (Texas HHS direct-to-manufacturer prescriptions), fire department medical consumables (Tampa), and multi-source generic pharmaceuticals distributed through authorized wholesalers (MMCAP). The issuing bodies span county health departments, state health and human services commissions, municipal fire departments, and state procurement offices coordinating multi-state cooperative purchasing.

Activity appears concentrated in the Southeast and Upper Midwest, with recent solicitations from Florida (Seminole County), Texas (state HHS), Florida (City of Tampa), and Minnesota (MMCAP, including Oregon participation). The most recent opportunity is the MMCAP RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with a response deadline of March 26, 2026; the Seminole County naloxone IFB (IFB60459723LAS) closed July 26, 2023; and the City of Tampa medical and first aid supplies IFB (26P00145) closed March 13, 2026 with an estimated contract value of $700,000 and a sheltered market set-aside for certified Small Local Business Enterprises. The code shows little direct evidence of sulfarsphenamine-specific demand; firms pursuing pharmaceutical supply opportunities should monitor cooperative purchasing vehicles such as MMCAP and track state HHS and county health department RFPs for generic drug procurement.